Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MGAM | O43451 | 1/20 | 0.50 |
| ▸ | SI | P14410 | 1/20 | 0.50 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.46 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3020462 | 0.86 | CYP1A2 (0.57) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL6449594 | 0.86 | CYP1A2 (0.57) | GAAMGAMSIMGAM2CYP1A2 | |
| Succinic Acid Diethyl Ester SCHEMBL22780 | 0.84 | GAA (0.67) | GAAMGAMSIMGAM2CYP1A2 | |
| Succinic Acid Diethyl Ester SCHEMBL27768067 | 0.84 | GAA (0.67) | GAAMGAMSIMGAM2CYP1A2 | |
| Succinic Acid Diethyl Ester SCHEMBL28197993 | 0.82 | GAA (0.57) | GAAMGAMSIMGAM2CYP1A2 | |
| SCHEMBL4445883 | 0.82 | DGKA (0.47) | ALDH1A1MAPK1SLC13A3EGLN1OR51E2 | |
| Succinic Acid Diethyl Ester SCHEMBL4324913 | 0.82 | GAA (0.63) | GAAMGAMSIMGAM2CYP1A2 | |
| Succinic Acid Diethyl Ester SCHEMBL21815758 | 0.82 | GAA (0.63) | GAAMGAMSIMGAM2CYP1A2 | |
| Succinic Acid Diethyl Ester SCHEMBL29494609 | 0.82 | GAA (0.63) | GAAMGAMSIMGAM2CYP1A2 | |
| Succinic Acid Diethyl Ester SCHEMBL27525301 | 0.82 | GAA (0.63) | GAAMGAMSIMGAM2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102892434-B | Method for preparing hyperpolarized substrates and MRI method | BRACCO IMAGING SPA | 2014-11-19 | — | — | CN | claimed |
| CN-102892434-A | Method for preparing hyperpolarized substrates and MRI method | BRACCO IMAGING SPA | 2013-01-23 | — | — | CN | claimed |
| US-20090048153-A1 | COMPOSITION FOR TREATING SULFUR MUSTARD TOXICITY AND METHODS OF USING SAME | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2009-02-19 | — | — | US | claimed |
| EP-1233767-B1 | PYRUVATE ESTER COMPOSITION AND METHOD OF USE FOR RESUSCITATION AFTER EVENTS OF ISCHEMIA AND REPERFUSION | XANTHUS LIFE SCIENCES INC (CA) | 2006-04-12 | — | — | EP | claimed |
| US-20050059738-A1 | Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion | XANTHUS LIFE SCIENCES, INC. (CA) | 2005-03-17 | — | — | US | claimed |
| WO-2025067483-A1 | AMIDE COMPOUNDS | 中国药科大学 | 2025-04-03 | — | — | WO | disclosed |
| EP-2555803-B1 | PROCESS FOR PREPARING HYPERPOLARIZED SUBSTRATES AND METHOD FOR MRI | BRACCO IMAGING SPA (IT) | 2018-09-12 | — | — | EP | disclosed |
| EP-2766050-B1 | PROCESS FOR THE PREPARATION OF HYPERPOLARIZED DERIVATIVES FOR USE IN MRI ANALYSIS | BRACCO IMAGING SPA (IT) | 2018-09-05 | — | — | EP | disclosed |
| US-9694090-B2 | Process for preparing hyperpolarized substrates and method for MRI | BRACCO IMAGING S.P.A. (IT) | 2017-07-04 | — | — | US | disclosed |
| US-9511154-B2 | Process for the preparation of hyperpolarized derivatives for use in MRI analysis | BRACCO IMAGING S.P.A. (IT) | 2016-12-06 | — | — | US | disclosed |
| CN-102892434-B | Method for preparing hyperpolarized substrates and MRI method | BRACCO IMAGING SPA | 2014-11-19 | — | — | CN | disclosed |
| US-20140257085-A1 | Process For The Preparation Of Hyperpolarized Derivatives For Use In MRI Analysis | BRACCO IMAGING S.P.A. (IT) | 2014-09-11 | — | — | US | disclosed |
| US-20120095261-A1 | Process for preparation of alpha-ketoglutaric acid | TIANJIN TIANCHENG PHARMACEUTICAL CO., LTD.(CHINA) | 2012-04-19 | — | — | US | disclosed |
| WO-2011124672-A1 | PROCESS FOR PREPARING HYPERPOLARIZED SUBSTRATES AND METHOD FOR MRI | BRACCO IMAGING SPA (IT) | 2011-10-13 | — | — | WO | disclosed |
| US-20090048153-A1 | COMPOSITION FOR TREATING SULFUR MUSTARD TOXICITY AND METHODS OF USING SAME | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2009-02-19 | — | — | US | disclosed |
| US-20080254198-A1 | Method of Preparing Creatine Ester Salts and Uses Thereof | BIO-ENGINEERED SUPPLEMENTS & NUTRITION, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080103202-A1 | METHOD OF PREPARING CREATINE ESTER SALTS AND USES THEREOF. | Ferguson, Chris (US) | 2008-05-01 | — | — | US | disclosed |
| WO-2006083381-A9 | COMPOSITION FOR TREATING SULFUR MUSTARD TOXICITY AND METHODS OF USING SAME | UNIV MARYLAND (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006083381-A2 | COMPOSITION FOR TREATING SULFUR MUSTARD TOXICITY AND METHODS OF USING SAME | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2006-08-10 | — | — | WO | disclosed |
| EP-0048159-A2 | Novel carboxyalkyl peptides and thioethers and ethers of peptides as antihypertensive agents | UNIVERSITY OF MIAMI (US) | 1982-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048153-A1 | COMPOSITION FOR TREATING SULFUR MUSTARD TOXICITY AND METHODS OF USING SAME | TST, SQOR, QSOX1 | GAA 4545/4885MGAM 3942/4885SI 1092/4885 |
| US-20080103202-A1 | METHOD OF PREPARING CREATINE ESTER SALTS AND USES THEREOF. | LIPA, CETP, CKMT1A; CKMT1B | GAA 1324/4885MGAM 491/4885SI 278/4885 |
| US-20140257085-A1 | Process For The Preparation Of Hyperpolarized Derivatives For Use In MRI Analysis | CA4, SLC16A3, SLC16A1 | GAA 569/4885MGAM 669/4885SI 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.